HER2-POSITIVE BREAST CANCER

This study is for people with HER2-positive stage II to IIIa breast cancer whose tumors completely disappear after initial chemotherapy and targeted therapy before surgery. The goal is to see if using fewer chemotherapy drugs after surgery can still keep the cancer from coming ba…

This early-phase study tests the safety of giving specially grown immune cells (T cells) to people with metastatic HER2-positive breast cancer. Participants first receive a vaccine made from their own immune cells plus two drugs (pepinemab and trastuzumab) to help the body fight …

This study tests whether radiation therapy followed by injecting two targeted antibodies (trastuzumab and pertuzumab) directly into the spinal fluid is safe and improves survival for people with HER2+ breast cancer that has spread to the lining of the brain and spine. About 33 pa…

This early-stage trial tests an experimental oral drug called ZN-A-1041, alone or with other cancer drugs, in people with HER2-positive advanced solid tumors (including breast cancer that has spread to the brain). The study aims to find safe doses and check how the drug works in …

This phase 2 trial is testing whether adding the immunotherapy drug atezolizumab to a standard combination of chemotherapy (paclitaxel) and two targeted drugs (trastuzumab and pertuzumab) is safe and effective for people with advanced HER2-positive breast cancer that has spread. …

This study tests a drug called T-DM1 in older adults (age 60+) with HER2-positive breast cancer after surgery. The goal is to see if it can prevent the cancer from coming back. About 111 participants received the drug, and researchers are tracking how long they stay cancer-free.

This study tests a new drug called BL-M07D1, alone or combined with other medicines, as a first treatment for people with advanced HER2-positive breast cancer that cannot be removed by surgery. The goal is to see if these treatments shrink tumors and how safe they are. About 83 a…

This early-phase trial tests a dendritic cell vaccine given directly into the spinal fluid for people with breast cancer that has spread to the lining of the brain (leptomeningeal disease). The vaccine is designed to train the immune system to attack cancer cells. The main goal i…

This study tests the drug trastuzumab deruxtecan in about 500 people with advanced HER2-positive breast cancer, some of whom also have brain metastases. The goal is to see how well the drug shrinks tumors and how long it keeps the cancer from growing. Participants receive the dru…

This study looks at whether women with aggressive breast cancers (triple-negative or HER2-positive) who have a complete response to chemotherapy can safely avoid sentinel lymph node biopsy. The trial will enroll 350 patients across Europe, all of whom will have breast-conserving …

This phase 3 trial compares a new drug called A166 to the standard drug T-DM1 in about 365 people with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body. Participants must have already been treated with trastuzumab and a taxane…

This Phase III trial is testing whether women and men with early-stage, low-risk HER2-positive breast cancer can safely skip radiation after breast-conserving surgery if they continue HER2-targeted therapy. About 1,300 participants are randomly assigned to receive either standard…

This phase 2 trial tests a two-step treatment for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. First, patients receive a strong drug called trastuzumab deruxtecan (T-DXd) to shrink the cancer. Then, they switch to a maintenance therapy …

This early-stage trial tests a treatment called HER2-CAR T cells for people with HER2-positive cancers that have spread to the brain or its lining. The cells are given directly into the brain's fluid spaces to try to kill tumor cells. The main goals are to find the safest dose an…

This Phase 3 trial tests whether adding tucatinib (a targeted pill) to standard therapy (trastuzumab and pertuzumab) can delay cancer growth in people with advanced HER2+ breast cancer. About 654 participants with inoperable or metastatic disease will receive either tucatinib or …

This Phase 2 trial is testing whether a combination of two targeted drugs (trastuzumab and pertuzumab) given as a single shot under the skin, along with standard hormone therapy, can prevent cancer from returning after surgery in people with early-stage, hormone receptor-positive…

This study tests whether adding tucatinib (a targeted pill) to standard T-DM1 therapy works better than T-DM1 alone for people with advanced HER2-positive breast cancer that has spread or can't be removed surgically. About 466 participants will receive either tucatinib or a place…

This study looks at whether women with triple-negative or HER2-positive breast cancer who have a complete response to chemotherapy can safely skip sentinel lymph node biopsy. The trial will compare standard surgery plus biopsy versus surgery alone, measuring how often cancer retu…

This early-phase study planned to test whether injecting the seasonal flu vaccine directly into breast tumors could help the immune system attack the cancer. It was designed for women with triple-negative or HER2+ breast cancer who were already scheduled for chemotherapy before s…

This Phase 3 trial is testing whether adding the immunotherapy drug atezolizumab to the targeted therapy trastuzumab emtansine (Kadcyla) can prevent breast cancer from returning in people with high-risk HER2-positive breast cancer. About 1,188 participants who still had cancer af…

This phase II trial is testing a less intense chemotherapy regimen for people with early-stage HER2-positive breast cancer. The experimental treatment combines paclitaxel with two targeted drugs (trastuzumab and pertuzumab), skipping the harsher anthracycline drugs. Researchers w…

This study looks at whether people with HER2-positive metastatic breast cancer who have had their cancer controlled for at least three years can safely stop their anti-HER2 therapy. About 82 participants will either stop or continue treatment to see if the cancer stays away for a…

This trial is testing whether giving a small dose of targeted radiation to a part of the breast tumor before standard chemotherapy can help the immune system fight the cancer more effectively. The study includes 40 people with high-risk or locally advanced breast cancer. After ra…

This study tests whether certain women with early-stage HER2-positive breast cancer can be treated with a targeted drug combination (PHESGO™) without chemotherapy. Researchers use specific markers to select patients whose tumors are highly dependent on the HER2 pathway. The goal …

This Phase 2 trial is testing a combination of two drugs—docetaxel (chemotherapy) and trastuzumab (a targeted therapy)—in 53 Nigerian women with HER2-positive breast cancer. The goal is to see how many women have no cancer left after treatment (called a complete response). The st…

This study looks at whether adding pegfilgrastim (a drug that increases white blood cells) to standard chemotherapy and trastuzumab can help the immune system better attack HER2-positive breast cancer before surgery. About 90 women with early-stage, operable breast cancer will ta…

This phase 3 trial tests whether a new drug called HS627 (a biosimilar) works as well as pertuzumab when given with trastuzumab and docetaxel before surgery for HER2-positive breast cancer. About 408 people with early-stage or locally advanced breast cancer took part. The main go…

This phase 2 trial tests whether a newer drug, margetuximab, combined with chemotherapy, works better than the standard trastuzumab combination for HER2-positive breast cancer before surgery. The study includes 174 people with stage II or III disease who have a specific genetic v…

This early-stage trial is testing a new drug called ELVN-002 in combination with trastuzumab and chemotherapy for people with advanced HER2-positive solid tumors, including breast, gastric, and colorectal cancers. The main goal is to find a safe dose and understand side effects. …

This Phase 3 trial compares a new drug called DB-1303 (also known as BNT323) to the current standard treatment T-DM1 in 228 people with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body. All participants have already been treat…

This study aimed to see if giving less chemotherapy before surgery, followed by targeted therapy, could work well for women with early-stage HER2-positive breast cancer. It planned to enroll women with tumors at least 2 cm or lymph node involvement. However, the study was withdra…

This pilot study is testing whether women with HER2-positive breast cancer who respond well to initial chemotherapy can safely receive less treatment after surgery. About 100 participants will receive a combination of drugs (paclitaxel, trastuzumab, and pertuzumab) before surgery…

This phase 2 trial is testing whether doctors can safely reduce the amount of chemotherapy given to people with HER2-positive breast cancer by using imaging scans to guide treatment. The study involves 462 participants with stage II or III disease who receive a combination of dru…

This phase 2 trial is testing whether adding the targeted drug pyrotinib to standard chemotherapy and trastuzumab before surgery can eliminate more cancer in women with HER2-positive early breast cancer. About 53 participants will receive the combination, and the main goal is to …

This pilot study tests a new type of breast scan called DBT-TOBI, which combines 3D mammography with light-based imaging. Researchers want to see if it can predict how well breast cancer responds to chemotherapy early in treatment. The study involves 30 women with HER2+ or triple…

This study tested whether a special PET scan using a radioactive tracer can predict how well patients with advanced HER2-positive breast cancer respond to the drug T-DM1. Ten women with cancer that had spread to other parts of the body received the scan before treatment. The goal…

This study explores whether routine brain MRIs and spinal taps can detect early signs of breast cancer spreading to the brain in people with HER2-positive breast cancer. Researchers will enroll 9 participants to see if these tests are feasible and well-tolerated. The goal is to c…

This study tests two different vaccines designed to prevent HER-2 positive breast cancer from coming back in people who have already completed initial treatment. About 119 participants who had surgery after chemotherapy will receive one of the two vaccines, followed by booster sh…

This study was designed to see if a combination of PET and MRI scans could detect early signs that treatment is working in people with stage IV HER2-positive breast cancer. The plan was to scan participants up to three times over six months and compare the images to standard meas…

This study investigates whether early changes on a PET scan can predict which patients with HER2-positive breast cancer will have a complete response to a combination of trastuzumab and pertuzumab given before surgery. Participants receive the two drugs and undergo PET scans at t…

This study looks at whether people with HER2-positive breast cancer can safely have fewer heart check-ups while on a specific type of treatment (trastuzumab without anthracyclines). About 190 participants will be followed to see if less monitoring leads to serious heart problems.…

This pilot study is testing whether a personalized blood test that looks for leftover tumor DNA can help doctors make better treatment decisions for people with early-stage breast cancer. About 34 participants with triple-negative or HER2-positive breast cancer will receive chemo…

This study looks at how the tumor microenvironment changes during chemotherapy in 30 patients with HER2-positive breast cancer. Researchers will take samples before, during, and after treatment to see what happens at the cellular level. The goal is to better understand how chemot…

This study follows 36 people with HER2-positive breast cancer who are receiving the drug T-DM1. Researchers want to learn how often and how severely the drug causes nerve damage (peripheral neuropathy), such as numbness, tingling, or pain. Participants will report their symptoms …

This study looks at how well a cardiopulmonary exercise test (CPET) can measure oxygen use in women with HER2-positive breast cancer who have mild heart problems from their cancer treatment. The goal is to see if this test can help predict how their heart and lungs will handle co…